首页> 外国专利> METHOD FOR PREDICTION OF RISK OF DEVELOPING PRIMARY OPEN-ANGLE GLAUCOMA STAGE III-IV

METHOD FOR PREDICTION OF RISK OF DEVELOPING PRIMARY OPEN-ANGLE GLAUCOMA STAGE III-IV

机译:预测原发性开角型青光眼III-IV期风险的方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medical diagnostics and provides a method of predicting risk of primary open angle glaucoma stage III-IV, comprising isolating DNA from peripheral venous blood of individuals of Russian nationality who are natives of Central Black Soil Region of Russian Federation, analysis of polymorphisms of genes -308G / A TNFα,+ 250A/G Ltα, +36A/G TNFR1, thus making a forecast of increased risk of primary open angle glaucoma stage III-IV in case of these genetic variants allele -308G TNFα or genotype -308GG TNFα, or +250A allele Ltα or genotype +250A Ltα, or a combination of alleles -308G TNFα genotype +250AA Ltα, or combination of genotypes -308GG TNFα allele +36A TNFR1; and low risk of developing primary open angle glaucoma stage III-IV predict detection of a combination of allele -308A TNFα allele +36A TNFR1 and allele +250G Ltα or a combination of allele -308A TNFα c allele +36A TNFR1.;EFFECT: invention provides higher prediction accuracy.;1 cl, 3 dwg
机译:发明领域本发明涉及医学诊断,并提供了一种预测原发性开角型青光眼III-IV期风险的方法,该方法包括从俄罗斯中部黑土地区居民的外周静脉血中分离DNA。俄罗斯联邦,对-308G / ATNFα,+ 250A / GLtα,+ 36A / G TNFR1基因多态性的分析,从而预测了在这些遗传变异为等位基因的情况下原发性开角型青光眼III-IV期的风险增加- 308GTNFα或基因型-308GGTNFα,或+ 250A等位基因Ltα或基因型+ 250ALtα,或等位基因-308GTNFα基因型+ 250AALtα的组合,或基因型-308GGTNFα等位基因+ 36A TNFR1的组合;原发性开角型青光眼III-IV期的低发生风险和低风险预测检测到等位基因-308ATNFα等位基因+ 36A TNFR1和等位基因+ 250GLtα的组合或等位基因-308ATNFαc等位基因+ 36A TNFR1的组合。提供更高的预测精度。; 1 cl,3 dwg

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号